Home › Research › Mild cognitive impairment
Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline
Jon Rodríguez-Antigüedad, Saül Martínez‐Horta, Arnau Puig‐Davi, Andrea Horta‐Barba, Javier Pagonabarraga, Teresa de Deus Fonticoba, Silvia Jesús, Marina Cosgaya et al.. Journal of Neurology, 2025-03-01
Topic: Risk, prevention and care in population studies
Abstract Background Parkinson’s Disease (PD)-associated subjective cognitive decline (PDSCD) is defined as cognitive complaints without objective cognitive impairment. Based on most studies, it is associated with a greater risk of cognitive decline and may represent a prodromal stage of cognitive impairment. Methods The main objectives are to identify cognitive progression patterns and clinical predictors of worse cognitive decline within a large PD-SCD cohort with a 4-year followup. All patients belong to the prospective observational multicenter study COPPADIS. Results A total of 198 PD-SCD subjects were analyzed. Mean age was 60.9, mean disease duration 5.2, and mean PD-Cognitive Rating Scale (PD-CRS) 97.6. Subjects were classified as Progressors if their Reliable Change Index was ≤ − 1.64 at year 4, and as non-Progressors if it was > − 1.64 (− 1.64 corresponded to − 16 on the PD-CRS). Progressors had significantly higher age, Movement Disorders Society-Unified PD Rating Scale (MDS-UPDRS) III, levodopa equivalent daily-dose, Non-Motor Symptom Scale total score, memory-related cognitive complaints, and prevalence of REM-sleep behavior disorder (RBD) at baseline. A linear mixed-effects model showed divergent cognitive trajectories between Progressors and non-Progressors (estimate = − 26.8; p < 0.001), with no differences in motor trajectories. In the binary regression model, age (OR = 1.09; p = 0.001), MDS-UPDRS III (OR = 1.05, p = 0.008), and RBD (OR = 2.55, p = 0.010) at baseline were independent predictors of cognitive progression. Conclusions Subjects with PD-SCD do not consistently show cognitive decline, but rather exhibit a heterogeneous progression. Age, MDS-UPDRS III and RBD significantly increase the risk of a more aggressive cognitive phenotype. Future research on biomarkers will help explore additional cognitive predictors in PD-SCD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rodríguez-Antigüedad, J., Martínez‐Horta, S., Puig‐Davi, A., Horta‐Barba, A., Pagonabarraga, J., Fonticoba, T. d. D., et al. (2025). Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline. Journal of Neurology. https://doi.org/10.1007/s00415-024-12808-0
Vancouver
Rodríguez-Antigüedad J, Martínez‐Horta S, Puig‐Davi A, Horta‐Barba A, Pagonabarraga J, Fonticoba TdD, et al. Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline. Journal of Neurology. 2025. doi:10.1007/s00415-024-12808-0. PMID: 40042541.
BibTeX
@article{rodriguezantiguedad2025-40042541,
author = {Rodríguez-Antigüedad, Jon and Martínez‐Horta, Saül and Puig‐Davi, Arnau and Horta‐Barba, Andrea and Pagonabarraga, Javier and Fonticoba, Teresa de Deus and Jesús, Silvia and Cosgaya, Marina and others},
title = {{Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline}},
journal = {Journal of Neurology},
year = {2025},
doi = {10.1007/s00415-024-12808-0},
pmid = {40042541},
url = {https://doi.org/10.1007/s00415-024-12808-0}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Based on most studies, it is associated with a greater risk of cognitive decline and may represent a prodromal stage of cognitive impairment.
- Results A total of 198 PD-SCD subjects were analyzed.
- Progressors had significantly higher age, Movement Disorders Society-Unified PD Rating Scale (MDS-UPDRS) III, levodopa equivalent daily-dose, Non-Motor Symptom Scale total score, memory-related cognitive complaints, and prevalence of REM-sleep behavior disorder (RBD) at baseline.
- Age, MDS-UPDRS III and RBD significantly increase the risk of a more aggressive cognitive phenotype.
Why it matters
In 198 patients with Parkinson's disease and subjective cognitive decline followed for 4 years, progressors had higher age, motor scores, levodopa dose, non-motor symptoms, memory complaints and REM-sleep behavior disorder at baseline. This identifies clinical predictors of cognitive decline, not a treatment, cure or prevention.
Study details
- Participants198
- Effect sizeOR = 1.09; OR = 1.05; OR = 2.55
- Evidence strengthModerate
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Neurology) |
| Journal's citation record | 2 / 4 | Journal of Neurology: journal h-index 208 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 198 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 10 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author M. J. González Palmás: h-index 9 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Hospital Clínic de Barcelona: institution h-index 827 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 40 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40042541) |
| Free to read | 2 / 2 | Free to read |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1007/s00415-024-12808-0
- PubMed: 40042541
- Original source →
- Free full text: Journal of Neurology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Mild cognitive impairment
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.